AAAAAA
Results:
1-12
|
Results: 12
Authors:
Hatse, S
Princen, K
Gerlach, LO
Bridger, G
Henson, G
De Clercq, E
Schwartz, TW
Schols, D
Citation: S. Hatse et al., Mutation of Asp(171) and Asp(262) of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100, MOLEC PHARM, 60(1), 2001, pp. 164-173
Authors:
Matthys, P
Hatse, S
Vermeire, K
Wuyts, A
Bridger, G
Henson, GW
De Clercq, E
Billiau, A
Schols, D
Citation: P. Matthys et al., AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice, J IMMUNOL, 167(8), 2001, pp. 4686-4692
Authors:
Wijnholds, J
Mol, CAAM
van Deemter, L
de Haas, M
Scheffer, GL
Baas, F
Beijnen, JH
Scheper, RJ
Hatse, S
De Clercq, E
Balzarini, J
Borst, P
Citation: J. Wijnholds et al., Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs, P NAS US, 97(13), 2000, pp. 7476-7481
Authors:
Balzarini, J
Degreve, B
Hatse, S
De Clercq, E
Breuer, M
Johansson, M
Huybrechts, R
Karlsson, A
Citation: J. Balzarini et al., The multifunctional deoxynucleoside kinase of insect cells is a target forthe development of new insecticides, MOLEC PHARM, 57(4), 2000, pp. 811-819
Authors:
Daelemans, D
Schols, D
Witvrouw, M
Pannecouque, C
Hatse, S
van Dooren, S
Hamy, F
Klimkait, T
De Clercq, E
Vandamme, AM
Citation: D. Daelemans et al., A second target for the peptoid Tat/transactivation response element inhibitor CGP64222: Inhibition of human immunodeficiency virus replication by blocking CXC-chemokine receptor 4-mediated virus entry, MOLEC PHARM, 57(1), 2000, pp. 116-124
Authors:
Zhang, Y
Hatse, S
De Clercq, E
Schols, D
Citation: Y. Zhang et al., CXC-chemokine receptor 4 is not a coreceptor for human herpesvirus 7 entryinto CD4(+) T cells, J VIROLOGY, 74(4), 2000, pp. 2011-2016
Authors:
Hatse, S
Schols, D
De Clercq, E
Balzarini, J
Citation: S. Hatse et al., 9-(2-phosphonylmethoxyethyl)adenine induces tumor cell differentiation or cell death by blocking cell cycle progression through the S phase, CELL GROWTH, 10(6), 1999, pp. 435-446
Authors:
Naesens, L
Hatse, S
Segers, C
Verbeken, E
De Clercq, E
Waer, M
Balzarini, J
Citation: L. Naesens et al., 9-(2-phosphonylmethoxyethyl)-N-6-cyclopropyl-2,6-diaminopurine: A novel prodrug of 9-(2-phosphonyl-methoxyethyl)guanine with improved antitumor efficacy and selectivity in choriocarcinoma-bearing rats, ONCOL RES, 11(4), 1999, pp. 195-203
Authors:
De Clercq, E
Andrei, G
Balzarini, J
Hatse, S
Liekens, S
Naesens, L
Neyts, J
Snoeck, R
Citation: E. De Clercq et al., Antitumor potential of acyclic nucleoside phosphonates, NUCLEOS NUC, 18(4-5), 1999, pp. 759-771
Authors:
Hatse, S
De Clercq, E
Balzarini, J
Citation: S. Hatse et al., Impact of 9-(2-phosphonylmethoxyethyl)adenine on (deoxy)ribonucleotide metabolism and nucleic acid synthesis in tumor cells, FEBS LETTER, 445(1), 1999, pp. 92-97
Role of antimetabolites of purine and pyrimidine nucleotide metabolism in tumor cell differentiation
Authors:
Hatse, S
De Clercq, E
Balzarini, J
Citation: S. Hatse et al., Role of antimetabolites of purine and pyrimidine nucleotide metabolism in tumor cell differentiation, BIOCH PHARM, 58(4), 1999, pp. 539-555
Authors:
Hatse, S
Naesens, L
De Clercq, E
Balzarini, J
Citation: S. Hatse et al., N-6-cyclopropyl-PMEDAP: A novel derivative of 9-(2-phosphonylmethoxyethyl)2-6-diaminopurine (PMEDAP) with distinct metabolic, antiproliferative, and differentiation-inducing properties, BIOCH PHARM, 58(2), 1999, pp. 311-323
Risultati:
1-12
|